§ 522.2478

per implant dose for use as in paragraph (d)(2)(ii)(A) of this section.

(E) 80 mg trenbolone acetate and 8 mg estradiol (one implant consisting of 5 pellets, each of 4 pellets containing 20 mg trenbolone acetate and 2 mg $\,$

estradiol, and 1 pellet containing 29 mg tylosin tartrate) per implant dose for use as in paragraph (d)(2)(ii)(B) of this section.

- (F) 200 mg trenbolone acetate and 20 mg estradiol (one implant consisting of 11 pellets, each of 10 pellets containing 20 mg trenbolone acetate and 2 mg estradiol, and 1 pellet containing 29 mg tylosin tartrate) per implant dose.
- (ii) Indications for use. (A) For increased rate of weight gain and improved feed efficiency.
- (B) For increased rate of weight gain. (iii) Limitations. Implant subcutaneously in ear only. Do not use in animals intended for subsequent breeding or in dairy animals. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
- (3) Pasture cattle (slaughter, stocker, and feeder steers and heifers)—(i) Amount. (A) 40 mg trenbolone acetate and 8 mg estradiol (one implant consisting of 2 pellets, each pellet containing 20 mg trenbolone acetate and 4 mg estradiol) per implant dose.
- (B) 40 mg trenbolone acetate and 8 mg estradiol (one implant consisting of 3 pellets, each of 2 pellets containing 20 mg trenbolone acetate and 4 mg estradiol, and 1 pellet containing 29 mg tylosin tartrate) per implant dose.
- (ii) *Indications for use*. For increased rate of weight gain.
- (iii) Limitations. Implant subcutaneously in ear only. Do not use in animals intended for subsequent breeding or in dairy animals. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.

[60 FR 4376, Jan. 23, 1995]

EDITORIAL NOTE: For FEDERAL REGISTER citations affecting §522.2477, see the List of CFR Sections Affected, which appears in the

Finding Aids section of the printed volume and at www.fdsys.gov.

§ 522.2478 Trenbolone acetate and estradiol benzoate.

- (a) *Specifications*. Each implant dose consists of:
- (1) 8 pellets, each pellet containing 25 milligrams (mg) trenbolone acetate and 3.5 mg estradiol benzoate.
- (2) 4 pellets, each pellet containing 25 mg trenbolone acetate and 3.5 mg estradiol benzoate.
- (b) Sponsor. See No. 054771 in §510.600(c) of this chapter.
- (c) Related tolerances. See §§ 556.240 and 556.739 of this chapter.
- (d) Conditions of use—(1) Steers fed in confinement for slaughter. (i) For an implant as described in paragraph (a)(1) of this section:
- (A) *Amount*. 200 mg trenbolone acetate and 28 mg estradiol benzoate.
- (B) *Indications for use*. For increased rate of weight gain and improved feed efficiency.
- (C) Limitations. Implant subcutaneously in ear only. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
- (ii) For an implant as described in paragraph (a)(2) of this section:
- (A) Amount. 100 mg trenbolone acetate and 14 mg estradiol benzoate.
- (B) *Indications for use*. For increased rate of weight gain.
- (C) Limitations. Implant subcutaneously in ear only. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
- (2) Heifers fed in confinement for slaughter—(i) Amount. 200 mg trenbolone acetate and 28 mg estradiol benzoate (as described in paragraph (a)(1) of this section).
- (ii) *Indications for use.* For increased rate of weight gain.
- (iii) Limitations. Implant subcutaneously in ear only. Not for subsequent breeding dairy or beef replacement heifers. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in

Food and Drug Administration, HHS

preruminating calves. Do not use in calves to be processed for yeal.

[67 FR 78972, Dec. 27, 2002, as amended at 69 FR 67818, Nov. 22, 2004; 79 FR 16197, Mar. 25, 2014]

§522.2483 Triamcinolone.

- (a) Specifications. Each milliliter of suspension contains 2 or 6 milligrams (mg) triamcinolone acetonide.
- (b) *Sponsor*. See No. 054628 in §510.600(c) of this chapter.
- (c) Conditions of use—(1) Dogs and cats—(i) Amount—(A) Intramuscular or subcutaneous. For inflammatory, arthritic, or allergic disorders, administer 0.05 to 0.1 mg per pound (/lb) of body weight as a single injection. For dermatologic disorders, administer 0.1 mg per pound (/lb) of body weight as a single injection. If symptoms recur, the dose may be repeated, or oral corticosteroid therapy may be instituted.
- (B) Intralesional. Administer 1.2 to 1.8 mg, divided in several injections around the lesion, spaced 0.5 to 2.5 centimeters apart, depending on lesion size. At any one site, the dose injected should not exceed 0.6 mg. and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 mg.
- (C) Intra-articular and intrasynovial. Administer 1 to 3 mg as a single injection, depending on the size of the joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage may be increased, not to exceed 3 mg.
- (ii) Indications for use. For the treatment of inflammation and related disorders, and the management and treatment of acute arthritis and allergic and dermatologic disorders.
- (iii) *Limitations*. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
- (2) Horses—(i) Amount—(A) Intramuscular or subcutaneous. Administer 0.01 to 0.02 mg/lb of body weight as a single injection. Usual dose is 12 to 20 mg.
- (B) Intra-articular and intrasynovial. Administer 6 to 18 mg as a single injection, depending on the size of the joint and severity of symptoms. After 3 or 4

days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage may be increased, not to exceed 18 mg.

- (ii) Indications for use. For the treatment of inflammation and related disorders
- (iii) *Limitations*. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[75 FR 10167, Mar. 5, 2010, as amended at 78 FR 21060, Apr. 9, 2013]

§522.2582 Triflupromazine.

- (a) *Specifications*. Each milliliter of solution contains 20 milligrams (mg) of triflupromazine hydrochloride.
- (b) *Sponsor*. See No. 054771 in §510.600(c) of this chapter.
- (c) Conditions of use—(1) Amount—(i) Dogs. Administer by intravenous injection at a dosage of 0.5 to 1 mg per pound of body weight daily, or by intramuscular injection at a dosage of 1 to 2 mg per pound of body weight daily.
- (ii) Cats. Administer by intramuscular injection at a dosage of 2 to 4 mg per pound of body weight daily.
- (iii) *Horses*. Administer by intravenous or intramuscular injection at a dosage of 10 to 15 mg per 100 pounds of body weight daily to a maximum dose of 100 mg.
- (2) Indications for use. For use in dogs, cats, and horses to relieve anxiety and to help control psychomotor overactivity as well as to increase the tolerance of animals to pain and pruritus. The drug is indicated in various office and clinical procedures which require the aid of a tranquilizer, antiemetic, or preanesthetic.
- (3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16197, Mar. 25, 2014]

§ 522.2610 Trimethoprim and sulfadiazine.

- (a) Specifications. Each milliliter (mL) contains:
- (1) 40 milligrams (mg) trimethoprim suspended in a solution containing 200 mg sulfadiazine; or